A Phase I, Dose-Escalation, Safety and Tolerability Study of COH29 in Patients With Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy Exists

Trial Profile

A Phase I, Dose-Escalation, Safety and Tolerability Study of COH29 in Patients With Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy Exists

Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs COH 29 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 02 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 27 Jun 2016 New source identified and integrated (NCT02112565).
    • 23 Jun 2016 Status changed from planning to recruiting, as reported in a Novonco Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top